Brokerages expect TG Therapeutics, Inc. (NASDAQ:TGTX) to announce earnings per share of ($0.46) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for TG Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.41) and the lowest estimate coming in at ($0.52). TG Therapeutics reported earnings of ($0.33) per share in the same quarter last year, which would suggest a negative year over year growth rate of 39.4%. The company is scheduled to issue its next earnings report on Monday, August 14th.

On average, analysts expect that TG Therapeutics will report full-year earnings of ($1.81) per share for the current fiscal year, with EPS estimates ranging from ($2.11) to ($1.45). For the next fiscal year, analysts anticipate that the business will post earnings of ($1.56) per share, with EPS estimates ranging from ($2.02) to ($1.16). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for TG Therapeutics.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Friday, May 5th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by $0.10. TG Therapeutics had a negative net margin of 60,613.16% and a negative return on equity of 135.31%. The firm had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million.

A number of brokerages have recently weighed in on TGTX. Jefferies Group LLC reissued a “buy” rating and set a $23.00 price target on shares of TG Therapeutics in a research report on Monday, June 5th. BidaskClub raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, July 24th. ValuEngine raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Zacks Investment Research cut shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 16th. Finally, FBR & Co reissued a “buy” rating on shares of TG Therapeutics in a research report on Thursday, May 18th. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $23.67.

Shares of TG Therapeutics (NASDAQ:TGTX) opened at 10.35 on Monday. TG Therapeutics has a 52 week low of $4.10 and a 52 week high of $15.35. The firm’s market capitalization is $638.14 million. The firm’s 50-day moving average is $11.10 and its 200 day moving average is $9.77.

In related news, CFO Sean A. Power sold 59,976 shares of the firm’s stock in a transaction on Monday, June 19th. The shares were sold at an average price of $11.09, for a total transaction of $665,133.84. Following the sale, the chief financial officer now directly owns 477,464 shares in the company, valued at $5,295,075.76. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 16.70% of the company’s stock.

Several large investors have recently modified their holdings of the company. Legal & General Group Plc raised its stake in shares of TG Therapeutics by 4.1% in the first quarter. Legal & General Group Plc now owns 9,801 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 384 shares during the last quarter. BB&T Securities LLC bought a new stake in shares of TG Therapeutics during the first quarter worth approximately $121,000. Hollencrest Securities LLC bought a new stake in shares of TG Therapeutics during the second quarter worth approximately $121,000. Thompson Davis & CO. Inc. bought a new stake in shares of TG Therapeutics during the first quarter worth approximately $154,000. Finally, Fox Run Management L.L.C. bought a new stake in shares of TG Therapeutics during the second quarter worth approximately $156,000. Institutional investors and hedge funds own 45.68% of the company’s stock.

WARNING: “Zacks: Brokerages Anticipate TG Therapeutics, Inc. (TGTX) Will Post Earnings of -$0.46 Per Share” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/08/07/zacks-brokerages-anticipate-tg-therapeutics-inc-tgtx-will-post-earnings-of-0-46-per-share.html.

TG Therapeutics Company Profile

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Get a free copy of the Zacks research report on TG Therapeutics (TGTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.